Fig. 5

In vivo antitumor activity. Antitumor effect (A) of tafasitamab (TAFA) 10 mg/kg i.p. twice a week, metronomic vinorelbine (mVNR) 4 mg/kg i.p. thrice a week, concomitant combination of tafasitamab and mVNR at each of the above doses, and human IgG1 isotype control i.p. twice weekly as controls for 42 days, on Toledo tumors subcutaneously xenotransplanted in CD nu/nu mice. Antitumor effect (B) of tafasitamab (TAFA) 10 mg/kg i.p. once a week, metronomic vinorelbine (mVNR) 2 mg/kg i.p. thrice a week, concomitant combination of tafasitamab and mVNR at each of the above doses, and human IgG1 isotype control i.p. once a week as controls for 42 days, on OCI-LY3 tumors subcutaneously xenotransplanted in CD nu/nu mice. Antitumor effect (C) of tafasitamab (TAFA) 10 mg/kg i.p. once a week, metronomic vinorelbine (mVNR) 2 mg/kg i.p. thrice a week, simultaneous combination of tafasitamab and mVNR at each of the above doses, and human IgG1 isotype control i.p. once a week as controls for 42 days, on SU-DHL10 tumors subcutaneously xenotransplanted in CD nu/nu mice. Overall survival (D) of CD nu/nu mice intravenously inoculated with SU-DHL10 cells and treated with tafasitamab (TAFA) 10 mg/kg i.p. once a week, metronomic vinorelbine (mVNR) 2 mg/kg i.p. thrice a week, simultaneous combination of tafasitamab and mVNR at each of the above doses, and human IgG1 isotype control i.p. once weekly as controls for 42 days (treatment period). *P < 0.05 with respect to IgG1 isotype controls. Symbols and bars, mean ± S.E.M.